Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn.

Now, her ongoing alliance with a telehealth company may be signifying a broader shift in US healthcare advertising, reflecting a changing of the guard in celebrity endorsements. The 23-time Grand Slam ...

Paris is emerging as a focal point for Europe’s next phase in oncology, as science, capital and industry converge at Campus Grand Parc.

Children as young as two with either sickle cell disease or thalassemia are now eligible for the gene therapy.

The US FDA has declined to approve Unicycive Therapeutics’ resubmitted NDA for OLC to treat hyperphosphatemia in CKD patients on dialysis.

The UK-US pharmaceuticals deal could cost the National Health Service (NHS) around £45bn ($60bn) within a decade and divert resources away from essential services, an analysis has suggested. The UK ...

Anthropic launches Claude Science as big tech companies increasingly eye expansion in the wider healthcare and life sciences space.

The EC has granted approval for Novartis’ Itvisma as a treatment for children two years and older, teenagers, and adults who have 5q SMA with a bi-allelic mutation in the SMN1 gene.

SK bioscience is set to lead the Gates Foundation-funded ROTOR project, an AI-based platform aimed at reducing uncertainty in vaccine-development decisions.

WHO is sponsoring a trial testing drugs for Bundibugyo virus, while adding the first Ebola diagnostic test to its emergency use list.

Sobi has received a CRL from the US FDA regarding its BLA for NASP, an investigational therapy intended for adults with uncontrolled gout.

Ipsen’s Memo acquisition is the second the former has signed this week alone, following its blockbuster Kartos buyout on 29 June.